| Literature DB >> 27306100 |
Heng Gee Lee1, Timothy William1,2, Jayaram Menon1, Anna P Ralph3, Eng Eong Ooi4, Yan'an Hou4, October Sessions4, Tsin Wen Yeo5,6,7.
Abstract
BACKGROUND: Central nervous system (CNS) infections are a significant contributor to morbidity and mortality globally. However, most published studies have been conducted in developed countries where the epidemiology and aetiology differ significantly from less developed areas. Additionally, there may be regional differences due to variation in the socio-economic levels, public health services and vaccination policies. Currently, no prospective studies have been conducted in Sabah, East Malaysia to define the epidemiology and aetiology of CNS infections. A better understanding of these is essential for the development of local guidelines for diagnosis and management.Entities:
Keywords: Central nervous system infections; Encephalitis; Meningitis; Meningo-encephalitis; Tuberculous meningitis
Mesh:
Year: 2016 PMID: 27306100 PMCID: PMC4910197 DOI: 10.1186/s12879-016-1640-x
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Molecular Tests Conducted on CSF Samples
| Viral pathogens | Bacterial pathogens | |
|---|---|---|
| First Level Tests Done for CSF samples | (i) herpes simplex virus 1 and 2, (ii) varicella zoster virus, (iii) enterovirus, (iv) Japanese encephalitis virus, (v) dengue virus, (vi) nipah virus, (vii) cytomegalovirus, (viii) West Nile virus, and (ix) bunyavirus | Not Done |
| Second Level Test Done for CSF samples | cytomegalovirus, Epstein Barr virus, La Crosse Virus, mumps, varicella zoster virus, measles,, human herpes virus 6, rabies, LCMV, California encephalitis group (Bunyavirus), Human Alphavirus group (Eastern, Western, Venezualan EEV), Bartonella, Flavivirus group, Enterovirus group,, St. Louis Encephalitis virus and West Nile Virus |
|
Demographic, vitals signs, laboratory and cerebrospinal fluid results on enrolment
| Tuberculous meningitis | Acute meningitis | Chronic meningitis | Encephalitis | Meningoencephalitis |
| |
|---|---|---|---|---|---|---|
| Number | 41 | 10 | 9 | 12 | 12 | |
| Demographic results | ||||||
| Age; years, (median, range) | 31 (13–64) | 33 (15–65) | 36.5 (22–67) | 38 (16–57) | 36 (14–62) |
|
| Males; (number, percentage) | 31 (75.6 %) | 6 (66.6 %) | 7 (77.7 %) | 9 (75 %) | 6 (50 %) |
|
| Fever History (number, percentage) | 32 (78 %) | 9 (100 %) | 7 (77.8 %) | 10 (83.3 %) | 8 (66.6 %) |
|
| Days of fever before presentation (median, range) | 14 (3–90) | 3 (1–19) | 35 (7–90) | 5 (2–21) | 4 (2–10) |
|
| Headache | 33 (80.5 %) | 8 (88.9 %) | 8 (88.9 %) | 8 (66.6 %) | 7 (63.6 %) |
|
| Coma (GCS < 11) | 12 (29.2 %) | 2 (22.2 %) | 0 (0 %) | 4 (33.3 %) | 3 (25 %) |
|
| HIV Positive (number, percentage) | 4 (9.8 %) | 3 (33.3 %) | 4 (44.4 %) | 2 (16.6 %) | 3 (27.7 %) |
|
| Vitals signs and laboratory results | ||||||
| Pulse Rate; median (range), (beats/min) | 85 (55–155) | 101 (50–160) | 88 (68–108) | 101 (65–140) | 99 (60–162) |
|
| Temperature; mean (range) (degrees Celsius) | 37.8 (36–40) | 38.5 (36.5–39) | 37.6 (36.2–38.2) | 38 (36.6–40.8) | 36.8 (36.8–39.3) |
|
| White blood cell count; mean (range), ×103/μL | 10.3 (4.3–25.3) | 10.8 (6–30.3) | 9.8 (4.3–13) | 15.2 (4.1 to 24.9) | 10 (4–22.2) |
|
| Hemoglobin; mean (range), (g/dl) | 12.4 (8.1–16.8) | 13.4 (7.4–15.9) | 12.1 (8–16.4) | 12 (8.2–15.9) | 12.1 (8.8–15.3) |
|
| Platelet; mean (range), ×109/L | 314 (83–582) | 251 (86–296) | 274 (212–443) | 193 (58–767) | 299 (61–470) |
|
| Lumbar Puncture Results | ||||||
| Opening Pressure (cm H2O) | 21 (8–65) | 6 (4–27) | 17 (4–40) | 15 (8–40) | 15 (3–34) |
|
| Total White Cell Count | 60 (0–1160) | 95 (20–220) | 40 (5–1050) | 50 (8–615) | 30 (0–305) |
|
| Neutrophil (Percentage) | 5 (0–92) | 20 (5–89) | 30 (0–99) | 10 (0–100) | 4 (0–30) |
|
| >50 % Neutrophils (number, percentage) | 7 (17.1 %) | 2 (22.2 %) | 3 (33.3 %) | 5 (41.7 %) | 6 (50 %) |
|
| Glucose (mmol/L) | 2 (0.2-4.6) | 3 (0.1-6) | 1.7 (0.2-3) | 3.8 (0.5-6.2) | 4 (2-5) |
|
| CSF:blood glucose ratio | 0.26 (0.09–0.51) | 0.45 (0.05–0.87) | 0.17 (0.1–0.31) | 0.55 (0.06–0.83) | 0.64 (0.32–0.8) |
|
| CSF:blood glucose ratio <50 % (number, percentage) | 37 (90.2) | 5 (55.5) | 8 (88.8) | 4 (33.3) | 2 (18.2) |
|
| Total Protein g/L | 1.6 (0.3–7.1) | 1.3 (0.5–4.2) | 1.2 (0.7–3.8) | 0.9 (0.4–8.3) | 0.95 (0.3–1.6) |
|
P < .05 by analysis of variance, the Kruskal-Wallis tests, χ 2 test or Fisher’s exact test comparing the groups
Classification and causes of CNS infections
| Aetiology | Total (%) |
|---|---|
| Infectious Cause | n=67 (80%) |
|
| 41 (50 %) |
|
| 14 (15 %) |
|
| 2 (2 %) |
|
| 3 (4 %) |
| Japanese Encephalitis virus | 1 (1 %) |
| Epstein–Barr virus | 1 (1 %) |
|
| 1 (1 %) |
|
| 3 |
|
| 1 |
| Immune-mediated cause | n = 2 (2 %) |
| ADEM | 1 (1 %) |
| NMDAR Encephalitis | 1 (1 %) |
| Unidentified | n = 15 (23 %) |
| Total | n = 84 |
Causes of CNS infections in immunocompetent versus immunocompromised patients
| Aetiology | Immunocompetenta
| Immunocompromisedb
| Total |
|---|---|---|---|
|
| 37 | 4 | 41 |
|
| 5 | 9 | 14 |
|
| - | 3 | 3 |
|
| 1 | 1 | 2 |
| Japanese Encephalitis virus | 1 | - | 1 |
| Epstein–Barr virus | 1 | - | 1 |
|
| 1 | - | 1 |
| ADEM | 1 | - | 1 |
| NMDAR Encephalitis | 1 | - | 1 |
| Unidentified | 12 | 3 | 15 |
aIncludes cases for whom immune status was unknown
bReasons for immunocompromised status: 15 HIV positive; 3 on steroid therapy; 1 post bone marrow transplant; 1 post splenectomy